Full Text View
Tabular View
No Study Results Posted
Related Studies
Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery
This study is currently recruiting participants.
Verified by Assistance Publique - Hôpitaux de Paris, September 2007
First Received: February 9, 2007   Last Updated: April 25, 2008   History of Changes
Sponsored by: Assistance Publique - Hôpitaux de Paris
Information provided by: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00438087
  Purpose

Facial palsy after surgical removal of cranial base tumors adherent to the nerve can partly be explained by inflammation.


Condition Intervention Phase
Facial Palsy
Drug: methylprednisolone
Phase III

Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-Pontine Angle Surgery

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Assessment of the facial function at 8 days postoperative [ Time Frame: at 8 days postoperative ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assessment of the facial function at 1 day postoperative [ Time Frame: at 1 day postoperative ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 380
Study Start Date: March 2007
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
2: Placebo Comparator
placebo versus methylprednisolone
Drug: methylprednisolone
methylprednisolone administrated intra and post operatively
1: Experimental
placebo versus methylprednisolone
Drug: methylprednisolone
methylprednisolone administrated intra and post operatively

Detailed Description:

Facial palsy after surgical removal of cranial base tumors adherent to the nerve can partly be explained by inflammation.

The purpose of this study was to assess the efficiency of corticosteroids to prevent facial palsy after such surgery and to identify the patients that will have the highest benefit from an anti-inflammatory treatment. This study will include patients undergoing surgery for a benign tumor of the cranial base (vestibular schwannoma). The efficiency of high dosage corticosteroids administered intravenously during and after surgery will be evaluated on the facial nerve function in comparison to a placebo. Pre operative and intra operative data will be collected and analysed in order to investigate possible predictive factors of response to the treatment. Introduction: After the surgical removal of a cerebella-pontine angle tumor (mainly vestibular schwannoma), and despite the anatomical integrity of the facial nerve, an immediate or delayed facial palsy may occur. This palsy may be explained by ischemia, edema, inflammation, or a neurotmesis (ruptured axons in an intact nerve sheet). This phenomenon is highly dependent on the size of the tumor. In our preliminary studies, we observed an immediate facial palsy in 16% and a palsy occurring at postoperative day 8 in 23% of the patients operated on for a vestibular schwannoma. Corticosteroids may decrease the inflammation and the edema around the nerve and reduce the incidence of the postoperative facial palsy. Their efficiency has already been demonstrated in idiopathic facial palsy. In a previously published study , a single dose of dexamethasone during surgery did not influence the facial function outcome. But the short period of the treatment do not allow definitive conclusions.

Objectives: The aim of this study is to analyze the effect of a corticosteroid (methyl prednisolone) administered intra- and postoperatively on the incidence of facial palsy after surgery of cerebella-pontine angle tumors and to determine intra operative prognostic factors for the facial function outcome. Material and Methods: A multi center, prospective, randomized, versus placebo, and double-blind study will be undertaken. Four-hundred patients undergoing surgery for a cerebellopontine angle tumor will be included during 23 months. Three university departments of otolaryngology (Hospital BEAUJON, CHU de Bordeaux, CHU de Tours) will participate. The pre operative assessment includes a clinical examination with the assessment of the facial function (in 6 grades according to House and BRACKMANN), an audiometry and a vestibular testing, and a cranial MRI with the classification of tumors in 4 stages according to their size. Patients will be randomized after information and with their consent. During surgery, the degree of nerve stretch (4 stages), the tumor adhesion to the nerve (4 stages) and the stimulation thresholds of the facial nerve with an electromyographic monitoring device (NIM Response 2, XOMED MEDTRONICS, Jacksonville, FL) will be recorded. All cases of facial nerve interruption during surgery will be excluded. In the treated group, one IV injection of methyl prednisolone at 1 mg/kg/day will be administered intra operatively and on postoperative days 1 and 2. The treatment will be continued on days 3 to 7 with the same dosage orally. Subsequently, 0.5 mg/kg/day at days 8 and 8, and 0.25 mg/kg/day at days 10 and 11. The facial function will be assessed on postoperative days 1, 8 and 30 clinically. Expected results: Considering the effect of corticosteroids in the idiopathic facial palsy and the effect of these agents on edema and inflammation, we expect and decrease in the incidence of immediate and delayed postoperative facial palsies. The intra operative stimulation thresholds may indicate a subgroup of patients for which the efficiency of the corticosteroids is higher than in the whole series.

Conclusion : The facial palsy after surgery of cerebellopontine angle tumors is the most frequent and the most significant morbidity. Corticosteroids may decrease the incidence of this complication.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults patients
  • surgery of base crane tumors
  • accept to participate
  • having health insurance

Exclusion Criteria:

  • pregnant woman
  • children
  • known allergy to steroids
  • preoperative facial palsy of grade >2
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00438087

Contacts
Contact: Alexis BOZORG GRAYELI, MD,PhD +33 (0)-1 40 87 56 29 alexis.bozorg-grayeli@bjn.aphp.fr

Locations
France
Assistance Publique Hopitaux De Paris Recruiting
CLICHY, France
Contact: Alexis BOZORG GRAYELLI, MD,PhD     +33(0)- 1 40 87 56 29     alexis.bozorg-grayeli@bjn.aphp.fr    
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Alexis BOZORG GRAYELI, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Department Clinical Research of Developpement ( Cécile KEDZIA )
Study ID Numbers: P051072
Study First Received: February 9, 2007
Last Updated: April 25, 2008
ClinicalTrials.gov Identifier: NCT00438087     History of Changes
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Facial palsy
Vestibular schwannoma
Anti-inflammatory drugs
Post surgery of vestibular schwannoma
or of cranial base tumors

Study placed in the following topic categories:
Mouth Diseases
Anti-Inflammatory Agents
Neuroma, Acoustic
Methylprednisolone
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Hormones
Neuroprotective Agents
Acoustic Neuroma
Signs and Symptoms
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Facies
Bell Palsy
Neurilemmoma
Methylprednisolone acetate
Glucocorticoids
Facial Paralysis
Herpesviridae Infections
Virus Diseases
Paralysis
Facial Nerve Diseases
Prednisolone
Neurologic Manifestations
DNA Virus Infections
Stomatognathic Diseases
Peripheral Nervous System Agents
Bell's Palsy

Additional relevant MeSH terms:
Mouth Diseases
Anti-Inflammatory Agents
Disease Attributes
Antineoplastic Agents
Methylprednisolone
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Hormones
Neuroprotective Agents
Signs and Symptoms
Pathologic Processes
Therapeutic Uses
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Facies
Bell Palsy
Nervous System Diseases
Gastrointestinal Agents
Methylprednisolone acetate
Glucocorticoids
Protective Agents
Facial Paralysis
Pharmacologic Actions
Herpesviridae Infections
Paralysis
Virus Diseases
Autonomic Agents
Facial Nerve Diseases

ClinicalTrials.gov processed this record on July 02, 2009